CITI/CALL/VIATRIS/12/0.1/19.06.25 Share Price

Warrant

DE000KH8MT53

Delayed Börse Stuttgart 08:15:47 23/05/2024 BST
0.08 EUR 0.00% Intraday chart for CITI/CALL/VIATRIS/12/0.1/19.06.25
Current month-38.46%
1 month-33.33%
Date Price Change
23/05/24 0.08 0.00%
22/05/24 0.08 -11.11%
21/05/24 0.09 -10.00%
20/05/24 0.1 +11.11%
17/05/24 0.09 0.00%

Delayed Quote Börse Stuttgart

Last update May 23, 2024 at 08:15 am

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying VIATRIS INC.
IssuerLogo Issuer Citi Citi
WKN KH8MT5
ISINDE000KH8MT53
Date issued 07/08/2023
Strike 12 $
Maturity 19/06/2025 (392 Days)
Parity 10 : 1
Emission price 0.1
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 0.24
Lowest since issue 0.021

Company Profile

Viatris Inc. is a global healthcare company. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. Its Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in China, Taiwan and Hong Kong. The JANZ segment consists of its operations in Japan, Australia and New Zealand. The Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies, including in Asia, Africa, Eastern Europe, Latin America and the Middle East, as well as the Company’s ARV franchise. Its portfolio comprises more than 1,400 approved molecules across a range of key therapeutic areas, including key brands and generics, including complex products. It operates around 40 manufacturing sites worldwide that produce oral solid doses, injectables, complex dosage forms and active pharmaceutical ingredients.
Sector
-
More about the company

Ratings for Viatris Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Consensus: Viatris Inc.

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
10
Last Close Price
10.88 USD
Average target price
12.33 USD
Spread / Average Target
+13.40%
Consensus